4-((2,4-difluorobenzyl)oxy)-6-methylpyridin-2(1H)-one | 586379-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-((2,4-difluorobenzyl)oxy)-6-methylpyridin-2(1H)-one
• 英文别名: 4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one；4-[(2,4-difluorophenyl)methoxy]-6-methyl-1H-pyridin-2-one
• CAS: 586379-20-6
• 化学式: C₁₃H₁₁F₂NO₂
• 分子量: 251.233
• InChiKey: GLOFGBXOHXBZHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((2,4-difluorobenzyl)oxy)-6-methylpyridin-2(1H)-one 在 sodium azide 、 sodium hydride 作用下， 以 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 、 叔丁醇 为溶剂， 125.0 ℃ 、1.24 MPa 条件下， 反应 27.01h， 生成 4-((2,4-difluorobenzyl)oxy)-6-methyl-1-((1-(3-(trifluoromethyl)-benzyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2(1H)-one
  参考文献：
  名称：

  Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases

  摘要：

  This study describes the discovery of novel dengue virus inhibitors targeting both a crucial viral protein protein interaction and an essential host cell factor as a strategy to reduce the emergence of drug resistance. Starting from known c-Src inhibitors, a virtual screening was performed to identify molecules able to interact with a recently discovered allosteric pocket on the dengue virus NS5 polymerase. The selection of cheap-to-produce scaffolds and the exploration of the biologically relevant chemical space around them suggested promising candidates for chemical synthesis. A series of purines emerged as the most interesting candidates able to inhibit virus replication at low micromolar concentrations with no Significant toxicity to the host cell. Among the identified antivirals, compound 16i proved to be 10 times More potent than ribavirin, showed a better selectivity index and represents the first-in-class DENV-NS5 allosteric inhibitor able to target both the virus NS5-NS3 interaction and the host kinases c-Src/Fyn.

  DOI：

  10.1021/acs.jmedchem.5b00108
• 作为产物：
  描述：

  4-羟基-6-甲基-2-吡喃酮 在 ammonium hydroxide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.25h， 生成 4-((2,4-difluorobenzyl)oxy)-6-methylpyridin-2(1H)-one
  参考文献：
  名称：

  Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases

  摘要：

  This study describes the discovery of novel dengue virus inhibitors targeting both a crucial viral protein protein interaction and an essential host cell factor as a strategy to reduce the emergence of drug resistance. Starting from known c-Src inhibitors, a virtual screening was performed to identify molecules able to interact with a recently discovered allosteric pocket on the dengue virus NS5 polymerase. The selection of cheap-to-produce scaffolds and the exploration of the biologically relevant chemical space around them suggested promising candidates for chemical synthesis. A series of purines emerged as the most interesting candidates able to inhibit virus replication at low micromolar concentrations with no Significant toxicity to the host cell. Among the identified antivirals, compound 16i proved to be 10 times More potent than ribavirin, showed a better selectivity index and represents the first-in-class DENV-NS5 allosteric inhibitor able to target both the virus NS5-NS3 interaction and the host kinases c-Src/Fyn.

  DOI：

  10.1021/acs.jmedchem.5b00108

文献信息

• Substituted pyridinones
  申请人：Devadas Balekudru

  公开号：US20050176775A1

  公开（公告）日：2005-08-11

  Disclosed are compounds of Formula I and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

  本发明涉及式I的化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5在此被定义。这些化合物可用于治疗由未调节的p38 MAP激酶和/或TNF活性引起或加剧的疾病和状况。本发明还涉及含有这些化合物的药物组合物、制备这些化合物的方法以及使用这些化合物的治疗方法。
• Diaryl substituted pyridinones
  申请人：Pfizer Inc

  公开号：US07629363B2

  公开（公告）日：2009-12-08

  Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3/R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

  本发明涉及化合物I的公开式及其药学上可接受的盐，其中R1、R2、R3/R4和R5的定义如下。这些化合物可用于治疗由未受调节的p38 MAP激酶和/或TNF活性引起或恶化的疾病和病况。本发明还公开了含有这些化合物的药物组合物、制备这些化合物的方法以及使用这些化合物的治疗方法。
• Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase
  作者：Shaun R. Selness、Rajesh V. Devraj、Joseph B. Monahan、Terri L. Boehm、John K. Walker、Balekudru Devadas、Richard C. Durley、Ravi Kurumbail、Huey Shieh、Li Xing、Michael Hepperle、Paul V. Rucker、Kevin D. Jerome、Alan G. Benson、Laura D. Marrufo、Heather M. Madsen、Jeff Hitchcock、Tom J. Owen、Lance Christie、Michele A. Promo、Brian S. Hickory、Edgardo Alvira、Win Naing、Radhika Blevis-Bal

  DOI：10.1016/j.bmcl.2009.08.082

  日期：2009.10

  The identification and evolution of a series of potent and selective p38 inhibitors is described. p38 inhibitors based on a N-benzyl pyridinone high-throughput screening hit were prepared and their SAR explored. Their design was guided by ligand bound co-crystals of p38 alpha. These efforts resulted in the identification of 12r and 19 as orally active inhibitors of p38 with significant efficacy in both acute and chronic models of inflammation. (C) 2009 Elsevier Ltd. All rights reserved.
• SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE
  申请人：Pharmacia Corporation

  公开号：EP1490064B1

  公开（公告）日：2009-11-18
• US7067540B2
  申请人：——

  公开号：US7067540B2

  公开（公告）日：2006-06-27